• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

What happened in optometry this week: April 22 - April 26

Blog
Article

Catch up on what happened in optometry during the week of April 22-April 26.

Catch up with what Optometry Times shared this week:

Ocugen completes dosing of subjects with GA in Cohort 2 of Phase 1/2 ArMaDa clinical trial of OCU410

By David Hutton, Managing Editor, Ophthalmology Times

Ocugen Inc announced dosing is complete in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD).1

Read here...

Study reports statistically significant improvements of DED symptoms with Bausch + Lomb’s LCD supplement

By Jordana Joy, Associate Editor

Bausch and Lomb announced that its proprietary blend of lutein, zeaxanthin isomers, curcumin, and vitamin D3 (LCD) received statistically significant results from a clinical study published in Frontiers in Ophthalmology, according to a news release. The prospective, randomized, double-blind, parallel, placebo-controlled study evaluated the efficacy and safety of the novel daily nutritional supplement formulated to address the symptoms of dry eye disease (DED). The primary endpoints were the change in tear production and participant reports of DED symptoms at day 56 of the trial.1

Read here...

Fact or fiction? A closer look at management options

By Michael Chaglasian, OD, FAAO, and Barbara M. Wirostko, MD, FARVO

Glaucoma is a slowly progressive optic neuropathy and a leading cause of irreversible blindness worldwide. Findings from our progressive longitudinal studies have demonstrated that a leading risk factor is a number, the intraocular pressure (IOP). We use this number to diagnose, treat, manage, and change therapies, including surgical recommendations. However, we only collect a single number at a single time point and, in many instances, only once every 3 to 6 months. IOP fluctuates and is a volatile and dynamic number that is often higher in the early waking hours.1

Read here...

The Myopia Collective: AOA, CooperVision unveil exciting new collaboration

By Michele Andrews, OD; Terri A. Gossard, OD, MS; and Emily Kaiser Maharjan, Assistant Managing Editor

Earlier this week, the American Optometric Association (AOA) and CooperVision revealed a partnership called The Myopia Collective to improve the standard of care for patients with myopia. For years, optometrists have aimed to correct myopia, but The Myopia Collective believe its time to embrace comprehensive treatment of the disease.

Michele Andrews, OD, vice president of professional and government affairs for CooperVision, and Terri A. Gossard, OD, MS, member of the AOA board of trustees, sat down with Optometry Times to discuss the goals and tactics of The Myopia Collective.

Watch here...

WVU Medicine planning expansion, relocation of WVU Eye Institute

By David Hutton, Managing Editor, Ophthalmology Times

The West Virginia Eye Institute announced it will expand its clinical, educational, and research efforts when it moves into a new location in Morgantown.

According to a university news release, the WVU Health System Board of Directors approved $233.5 million to fund the construction of a multi-center outpatient facility. It will also include a multi-level parking garage with more than 1,100 spaces.1

Read here...

Related Videos
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Shelley Cutler, OD, FAAO, outlines her key takeaways from this year's IKA symposium
© 2024 MJH Life Sciences

All rights reserved.